| __timestamp | Bio-Techne Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 570979 |
| Thursday, January 1, 2015 | 144969000 | 2185000 |
| Friday, January 1, 2016 | 162364000 | 4554000 |
| Sunday, January 1, 2017 | 188462000 | 3605000 |
| Monday, January 1, 2018 | 210850000 | 5527000 |
| Tuesday, January 1, 2019 | 240515000 | 5234000 |
| Wednesday, January 1, 2020 | 255497000 | 6126000 |
| Friday, January 1, 2021 | 298182000 | 6784000 |
| Saturday, January 1, 2022 | 349103000 | 7592000 |
| Sunday, January 1, 2023 | 366887000 | 11450000 |
| Monday, January 1, 2024 | 389335000 |
Data in motion
In the ever-evolving landscape of biotechnology, cost efficiency remains a pivotal factor for success. Bio-Techne Corporation and Travere Therapeutics, Inc. offer a compelling case study in this regard. Over the past decade, Bio-Techne has demonstrated a robust growth trajectory, with its cost of revenue increasing by approximately 266% from 2014 to 2023. This reflects a strategic expansion and scaling of operations. In contrast, Travere Therapeutics, Inc. has shown a more modest increase of around 1,900% in the same period, albeit from a much smaller base, indicating a different growth phase.
The data reveals a stark contrast in scale and growth strategies between these two companies. While Bio-Techne's cost efficiency is evident in its consistent upward trend, Travere's figures suggest a more volatile path, possibly due to its focus on niche markets. Missing data for 2024 highlights the dynamic nature of this industry, where projections can shift rapidly.
Cost Insights: Breaking Down Eli Lilly and Company and Bio-Techne Corporation's Expenses
Cost Insights: Breaking Down Merck & Co., Inc. and Bio-Techne Corporation's Expenses
Cost of Revenue Comparison: Merck & Co., Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Bio-Techne Corporation vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Mesoblast Limited
Cost of Revenue: Key Insights for Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: Catalent, Inc. vs Travere Therapeutics, Inc.
Telix Pharmaceuticals Limited vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Iovance Biotherapeutics, Inc. vs Travere Therapeutics, Inc.
Analyzing Cost of Revenue: Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.